Your browser doesn't support javascript.
loading
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro, Gilberto; Rizvi, Naiyer A; Schmid, Peter; Syrigos, Konstantinos; Martin, Claudio; Yamamoto, Nobuyuki; Cheng, Ying; Moiseyenko, Vladimir; Summers, Yvonne; Vynnychenko, Ihor; Lee, Sung Yong; Bryl, Maciej; Zer, Alona; Erman, Mustafa; Timcheva, Constanta; Raja, Rajiv; Naicker, Kirsha; Scheuring, Urban; Walker, Jill; Mann, Helen; Chand, Vikram; Mok, Tony.
Afiliação
  • de Castro G; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. Electronic address: gilberto.castro@usp.br.
  • Rizvi NA; Columbia University Medical Center, New York, New York.
  • Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Syrigos K; 3rd Department of Medicine, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
  • Martin C; Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Yamamoto N; Wakayama Medical University, Wakayama, Japan.
  • Cheng Y; Cancer Hospital of Jilin Province, Changchun, People's Republic of China.
  • Moiseyenko V; Clinical Research Center, Pesochny, St. Petersburg, Russian Federation.
  • Summers Y; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Vynnychenko I; Sumy State University, Sumy Regional Oncology Centre, Sumy, Ukraine.
  • Lee SY; Korea University, Seoul, South Korea.
  • Bryl M; E. J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland.
  • Zer A; Rabin Medical Center, Petah Tikva, Israel.
  • Erman M; Hacettepe University Cancer Institute, Ankara, Turkey.
  • Timcheva C; Medical Oncology Clinic, MHAT, Nadezhda, Sofia, Bulgaria.
  • Raja R; AstraZeneca, Gaithersburg, Maryland.
  • Naicker K; AstraZeneca, Cambridge, United Kingdom.
  • Scheuring U; AstraZeneca, Cambridge, United Kingdom.
  • Walker J; AstraZeneca, Cambridge, United Kingdom.
  • Mann H; AstraZeneca, Cambridge, United Kingdom.
  • Chand V; AstraZeneca, Gaithersburg, Maryland.
  • Mok T; State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, People's Republic of China.
J Thorac Oncol ; 18(1): 106-119, 2023 01.
Article em En | MEDLINE | ID: mdl-36240972
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article